Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial

NCT04361552 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT04361552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04361552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial
Lead sponsor
Emory University
Phase
Phase 3
Overall status
Withdrawn
Start date
April 7, 2020
Completion date
June 2, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebrovascular accident, chronic obstructive pulmonary disease, chronic renal failure, coronary artery disease, diabetes mellitus, malignant neoplasm, sars coronavirus 2 infection